Hongjuan Zhao1, Donna M Peehl. 1. Department of Urology, Stanford University School of Medicine, Stanford, California 94305-5118, USA.
Abstract
BACKGROUND: Cancer-associated stroma contributes to the malignant behavior of adenocarcinomas of the prostate and other organs. CD90 is a marker of mesenchymal stem cells (MSCs) and its expression is higher in prostate cancer stroma compared to normal tissue. Cultured prostate cancer-associated fibroblasts (CAFs) expressing high versus low levels of CD90 were analyzed for an MSC-like or tumor-promoting phenotype. METHODS: CD90(hi) and CD90(lo) cells were collected by fluorescence-activated cell sorting (FACS). Expression of genes associated with MSCs and/or tumor-promoting activities was measured by quantitative polymerase chain reaction (qPCR). Effects of stromal cell co-culture or conditioned media were tested on BPH-1 epithelial cells. RESULTS: The pattern of gene expression did not support the hypothesis that CD90(hi) cells were MSCs. However, CD90(hi) cells expressed higher levels of many genes associated with tumor promotion, including cytokines, angiogenic factors, hedgehog signaling components, and transforming growth factor (TGF)-beta. Co-culture or conditioned medium from CD90(hi) cells increased CXCR4 expression in BPH-1 cells, at least in part due to TGF-beta, and protected BPH-1 cells from apoptosis. CONCLUSIONS: Our results suggest that the elevated expression of CD90 previously observed in the cancer-associated stroma of the human prostate is biologically significant. Although our results do not support the idea that CD90(hi) cells cultured from the cancer stroma are MSCs, our findings suggest that the phenotype of these cells is more tumor-promoting than that of cells expressing low CD90.
BACKGROUND:Cancer-associated stroma contributes to the malignant behavior of adenocarcinomas of the prostate and other organs. CD90 is a marker of mesenchymal stem cells (MSCs) and its expression is higher in prostate cancer stroma compared to normal tissue. Cultured prostate cancer-associated fibroblasts (CAFs) expressing high versus low levels of CD90 were analyzed for an MSC-like or tumor-promoting phenotype. METHODS:CD90(hi) and CD90(lo) cells were collected by fluorescence-activated cell sorting (FACS). Expression of genes associated with MSCs and/or tumor-promoting activities was measured by quantitative polymerase chain reaction (qPCR). Effects of stromal cell co-culture or conditioned media were tested on BPH-1 epithelial cells. RESULTS: The pattern of gene expression did not support the hypothesis that CD90(hi) cells were MSCs. However, CD90(hi) cells expressed higher levels of many genes associated with tumor promotion, including cytokines, angiogenic factors, hedgehog signaling components, and transforming growth factor (TGF)-beta. Co-culture or conditioned medium from CD90(hi) cells increased CXCR4 expression in BPH-1 cells, at least in part due to TGF-beta, and protected BPH-1 cells from apoptosis. CONCLUSIONS: Our results suggest that the elevated expression of CD90 previously observed in the cancer-associated stroma of the human prostate is biologically significant. Although our results do not support the idea that CD90(hi) cells cultured from the cancer stroma are MSCs, our findings suggest that the phenotype of these cells is more tumor-promoting than that of cells expressing low CD90.
Authors: Jennifer A Tuxhorn; Stephanie J McAlhany; Truong D Dang; Gustavo E Ayala; David R Rowley Journal: Cancer Res Date: 2002-06-01 Impact factor: 12.701
Authors: Lian Fan; Carmen V Pepicelli; Christian C Dibble; Winnie Catbagan; Jodi L Zarycki; Robert Laciak; Jerry Gipp; Aubie Shaw; Marilyn L G Lamm; Alejandro Munoz; Robert Lipinski; J Brantley Thrasher; Wade Bushman Journal: Endocrinology Date: 2004-05-07 Impact factor: 4.736
Authors: Yirong Li; Caihong X Li; Huihui Ye; Fei Chen; Jonathan Melamed; Yi Peng; Jinsong Liu; Zhengxin Wang; Hui C Tsou; Jianjun Wei; Paul Walden; Michael J Garabedian; Peng Lee Journal: J Cell Mol Med Date: 2008-02-08 Impact factor: 5.310
Authors: Ubaldo E Martinez-Outschoorn; Casey Trimmer; Zhao Lin; Diana Whitaker-Menezes; Barbara Chiavarina; Jie Zhou; Chengwang Wang; Stephanos Pavlides; Maria P Martinez-Cantarin; Franco Capozza; Agnieszka K Witkiewicz; Neal Flomenberg; Anthony Howell; Richard G Pestell; Jaime Caro; Michael P Lisanti; Federica Sotgia Journal: Cell Cycle Date: 2010-09-09 Impact factor: 4.534
Authors: Ines A Silva; Shoumei Bai; Karen McLean; Kun Yang; Kent Griffith; Dafydd Thomas; Christophe Ginestier; Carolyn Johnston; Angela Kueck; R Kevin Reynolds; Max S Wicha; Ronald J Buckanovich Journal: Cancer Res Date: 2011-04-15 Impact factor: 12.701
Authors: Giulia Grisendi; Rita Bussolari; Elena Veronesi; Serena Piccinno; Jorge S Burns; Giorgio De Santis; Pietro Loschi; Marco Pignatti; Fabrizio Di Benedetto; Roberto Ballarin; Carmela Di Gregorio; Valentina Guarneri; Lino Piccinini; Edwin M Horwitz; Paolo Paolucci; Pierfranco Conte; Massimo Dominici Journal: Am J Cancer Res Date: 2011-05-28 Impact factor: 6.166
Authors: Woosook Kim; David A Barron; Rebeca San Martin; Keith S Chan; Linda L Tran; Feng Yang; Steven J Ressler; David R Rowley Journal: Proc Natl Acad Sci U S A Date: 2014-10-13 Impact factor: 11.205
Authors: Laura E Pascal; Young Ah Goo; Ricardo Zn Vêncio; Laura S Page; Amber A Chambers; Emily S Liebeskind; Thomas K Takayama; Lawrence D True; Alvin Y Liu Journal: BMC Cancer Date: 2009-09-08 Impact factor: 4.430